Kannalife Sciences Announces Feasibility Study With Catalent Pharma Solutions for the Development of a Novel Cannabinoid Therapeutic Agent to Treat CTE and HE NEW YORK, Feb. 29, 2016 (GLOBE NEWSWIRE) -- Kannalife Sciences, Inc. (“Kannalife”), a Phyto-Medical Company, is pleased to announce the progress of its ongoing feasibility study being performed by...